홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

플루바스타틴

(6E)-7-(3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid

HCID 5353627
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
93957-54-1
표준 SMILES
CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21
InChIKey
FJLGEFLZQAZZCD-VAWYXSNFSA-N
분자식
C24H26FNO4
평균 분자량
411.5 g/mol
단동위원소 질량
411.18458647

개요

7-[3-(4-fluorophenyl)-1-propan-2-yl-2-indolyl]-3,5-dihydroxy-6-heptenoic acid is a member of pyrroles.

이름 및 식별자

우선 이름
(6E)-7-(3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid
IUPAC
(E)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
현지명
플루바스타틴
영어명
Fluvastatin
분자식
C24H26FNO4
분자량
411.47

이름 및 동의어

CHEBI:38562(6E)-7-(3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acidRefChem:9348821025085-49-77-[3-(4-fluorophenyl)-1-(propan-2-yl)-1h-indol-2-yl]-3,5-dihydroxyhept-6-enoic acidSCHEMBL2848CHEMBL2220442CHEBI:95159(3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-yl-2-indolyl]-3,5-dihydroxy-6-heptenoic acidBDBM50622531EN300-295528
이름 더 보기
플루바스타틴LescolLipaxanLescholPrimexinT-PowderFLUVASTATINMolysulfideMoly Powder BFLUVASTATIN NAFluvastatin-D7
Q27117899(6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1h-indol-2-yl]-3,5-dihydroxyhept-6-enoicacid7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid, sodium salt

데이터베이스 식별자

CAS
93957-54-1
PubChem CID
5353627
ChEMBL
CHEMBL2220442
ChEBI
CHEBI:95159

물성

구조 계산 물성

XLogP
3.5
극성 표면적
82.7 Ų
수소 결합 공여자 수
3
수소 결합 수용자 수
5
회전 가능 결합 수
8
무거운 원자 수
30
형식 전하
0
복잡도
590

실험 및 물리화학적 성질

DrugsPharmaceuticals
Melting Point194-197 °C
Dissociation Constants4.31

물리화학적 성질

녹는점
193.9 · 193.9-196.9 °C
끓는 점
681.8 · 681.8±55.0 °C(Predicted)
밀도
1.23 · 1.23±0.1 g/cm3(Predicted)
저장 조건
2 · 2-8°C
용해도
25 mg/ml · Water 25 mg/ml DMSO 100 mg/ml Ethanol 25 mg/ml
물리적 상태
가루
산도 계수 (pKa)
4.27 · 4.27±0.10(Predicted)
색상
Light yellow to yellow
EPA
6 · 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]- 3,5-dihydroxy-, (3R,5S,6E)-rel- (93957-54-1)

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

안전 데이터

유해 물질 데이터
93957-54-1(Hazardous Substances Data)

화학 및 산업

약리 정보

Protein Binding98% bound to plasma proteins. At therapeutic concentrations, the protein binding of fluvastatin is not affected by warfarin, salicylic acid and glyburide.
Pharmacodynamics · 1건

Fluvastatin, the first synthetically-derived HMG-CoA reductase inhibitor, is a hydrophilic, acidic, antilipemic agent used to lower cholesterol and triglyceride levels associated with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb), to slow the progression of coronary atherosclerosis in patients with CHD and as secondary prevention therapy in patients with CHD to reduce the risk of requiring coronary revascularization procedures. Although similar to lovastatin, simvastatin, and pravastatin, fluvastatin has a shorter half-life, no active metabolites, extensive protein binding, and minimal CSF penetration. Fluvastatin acts primarily in the liver. It is prepared as a racemate of two erythro enantiomers of which the 3R,5S enantiomer exerts the pharmacologic effect.

Mechanism of Action · 1건

Fluvastatin selectively and competitively inhibits the hepatic enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate, the rate-limiting step in cholesterol biosynthesis. Inhibition results in a decrease in hepatic cholesterol levels which stimulates the synthesis of LDL receptors and increases hepatic uptake of LDL cholesterol. The end result is decreased levels of plasma total and LDL cholesterol.

Biological Half-Life3 hours
Metabolism/Metabolites · 1건

Undergoes hepatic metabolism primarily via hydroxylation of the indole ring at the 5- and 6-positions to 5-hydroxy fluvastatin and 6-hydroxy fluvastatin, respectively. N-dealkylation to N-desisopropyl fluvastatin and beta-oxidation of the side chain also occurs. Metabolized primarily by the CYP2C9 isozyme system (75%), and to a lesser extent by CYP3A4 (~20%) and CYP2C8 (~5%). Hydroxylated metabolites retain some pharmcological activity, but are present as conjugates (glucuronides and sulfates) in the blood and are rapidly eliminated via bile into feces. Both enantiomers of fluvastatin are metabolized in a similar manner. Fluvastatin also undergoes glucuronidation via UGT enzymes.

Absorption, Distribution and Excretion · 4건

Rapidly and almost completely absorbed (> 90%), but undergoes extensive first pass metabolism. Bioavailability is 24% (range 9-50%) when a 10 mg dose is given. The mean relative bioavailability of the extended-release tablet is 29% (range: 9% to 66%) compared to an immediate-release capsule administered under fasting conditions. When given orally, fluvastatin reaches peak concentrations (Tmax) in less than one hour. Taking the extended release tablet with a high-fat meal will delay absorption (Tmax = 6 hours) and increase bioavailability by approximately 50%. However, the maximum concentration of fluvastatin sodium extended-release tablets seen after a high fat meal is less than the peak concentration following a single dose or twice daily dose of the 40 mg fluvastatin capsule.

When orally administered, fluvastatin is primarily excreted in the faces ( ~90%) as metabolites, with less than 2% present as unchanged drug. Approximately 5% was recovered in the urine.

0.35 L/kg

0.8 L/h/kg

응용 분야 · 2건

용도A synthetic HMG-CoA reductase inhibitor

일반 설명Fluvastatin, [R*,S*-(E)]-(±)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid monosodium salt (Lescol), is very similarto pravastatin. It possesses a heptanoic acid side chain thatis superimposable over the lactone ring found in lovastatinand simvastatin. This side chain is recognized by HMGCoAreductase. Also, much like pravastatin, the CNS sideeffects of this lipid-lowering agent are much lower thanthose of the agents that possess a lactone ring as part of theirarchitectural design.

상·하류 제품 정보

상류 원료

수산화나트륨이소프로필아닐린플루오르벤젠클로로아세틸 클로라이드

관련 반응

10건
반응 기록 만들기
HRID 47594 반응식
HRID 47594반응물로
HRID 220009 반응식
HRID 220009반응물로
HRID 530260 반응식
HRID 530260반응물로
HRID 661195 반응식
HRID 661195반응물로
HRID 984878 반응식
HRID 984878반응물로
HRID 2219846 반응식
HRID 2219846반응물로
HRID 2219847 반응식
HRID 2219847반응물로
HRID 2247086 반응식
HRID 2247086반응물로
이전1 / 2 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트